• Je něco špatně v tomto záznamu ?

Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data

V. Maisnar, L. Pour, I. Spicka, T. Jelinek, J. Minarik, A. Jungova, M. Stork, J. Straub, J. Radocha, T. Pika, L. Pospisilova, S. Nair, P. Kunovszki, R. Hajek

. 2023 ; 23 (2) : 145-153. [pub] 20221106

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004329

BACKGROUND: Although novel therapies improved prognosis of multiple myeloma (MM) patients, clinical outcomes in the multi-refractory population are still poor. PATIENTS AND METHODS: We reviewed data from the Czech Registry of Monoclonal Gammopathies, identified and characterized triple-class exposed (3CE) relapsed/refractory MM patients, treatment patterns after 3CE, assessed overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), explored cohorts with and without triple- and penta-refractoriness. RESULTS: In 83 3CE patients who started subsequent therapies, the median OS was 14.2 months (95% CI, 8.5-19.9), PFS 6.2 months (95% CI, 3.9-8.5), and TTNT 7.2 months (95% CI, 4.6-9.8). Triple- and penta-class refractory patients had a significantly worse prognosis in all outcomes. Their life expectancy was shorter, the disease progression started earlier, and the TTNT was shorter, which increased likelihood of becoming refractory to more therapies. Time-to-event results from the first index date and all index dates analyses were very similar. CONCLUSION: Similar to previous studies from the US and Europe, our results show a high disease burden. Introduction of novel therapies, such as CAR-T cells, new bispecific and trispecific monoclonal antibodies, and other drugs, is expected to bring significant benefits to these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004329
003      
CZ-PrNML
005      
20230425141308.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2022.11.001 $2 doi
035    __
$a (PubMed)36567210
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Maisnar, Vladimir $u Fourth Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
245    10
$a Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data / $c V. Maisnar, L. Pour, I. Spicka, T. Jelinek, J. Minarik, A. Jungova, M. Stork, J. Straub, J. Radocha, T. Pika, L. Pospisilova, S. Nair, P. Kunovszki, R. Hajek
520    9_
$a BACKGROUND: Although novel therapies improved prognosis of multiple myeloma (MM) patients, clinical outcomes in the multi-refractory population are still poor. PATIENTS AND METHODS: We reviewed data from the Czech Registry of Monoclonal Gammopathies, identified and characterized triple-class exposed (3CE) relapsed/refractory MM patients, treatment patterns after 3CE, assessed overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), explored cohorts with and without triple- and penta-refractoriness. RESULTS: In 83 3CE patients who started subsequent therapies, the median OS was 14.2 months (95% CI, 8.5-19.9), PFS 6.2 months (95% CI, 3.9-8.5), and TTNT 7.2 months (95% CI, 4.6-9.8). Triple- and penta-class refractory patients had a significantly worse prognosis in all outcomes. Their life expectancy was shorter, the disease progression started earlier, and the TTNT was shorter, which increased likelihood of becoming refractory to more therapies. Time-to-event results from the first index date and all index dates analyses were very similar. CONCLUSION: Similar to previous studies from the US and Europe, our results show a high disease burden. Introduction of novel therapies, such as CAR-T cells, new bispecific and trispecific monoclonal antibodies, and other drugs, is expected to bring significant benefits to these patients.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a registrace $7 D012042
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Spicka, Ivan $u Department of Hematology, First Faculty of Medicine, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Jelinek, Tomas $u Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Jungova, Alexandra $u Department of Hemato-Oncology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Straub, Jan $u Department of Hematology, First Faculty of Medicine, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Radocha, Jakub $u Fourth Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Pika, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic
700    1_
$a Nair, Sandhya $u Janssen Global Services, Beerse, Belgium
700    1_
$a Kunovszki, Peter $u Janssen Global Services, Budapest, Hungary
700    1_
$a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Electronic address: roman.hajek@fno.cz
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 23, č. 2 (2023), s. 145-153
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36567210 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141304 $b ABA008
999    __
$a ok $b bmc $g 1924796 $s 1190538
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 23 $c 2 $d 145-153 $e 20221106 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace